FORMA Therapeutics is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of transformative medicines for patients with rare hematologic diseases and cancers. The company is advancing FT-4202, a pyruvate kinase-R (PKR) activator in clinical development as a potential disease-modifying therapy for sickle cell disease; a Phase 1/2 study is currently enrolling patients. Data presented at the 2019 American Society of Hematology Annual Meeting showed FT-4202 activates PKR, has a simultaneous effect on hemoglobin oxygen affinity and ATP levels, and was safe and well-tolerated in healthy subjects. FORMA's pipeline also includes FT-7051, a selective inhibitor of CBP/p300 for androgen receptor-driven cancers including AR-v7 mCRPC, olutasidenib, a next-generation IDH1m inhibitor for gliomas, relapsed/refractory AML, MDS and other IDH1m solid tumors, and multiple preclinical programs. The company describes a validated proprietary R&D engine that combines deep biology insight, chemistry expertise and clinical development capabilities to create differentiated drug candidates. The recent $100 million Series D financing will support ongoing clinical development and broader pipeline advancement. Forma Therapeutics develops small-molecule cancer therapeutics using a novel approach to access high-value drug targets. The company integrates innovative drug discovery technologies with oncology expertise to enable efficient screening, discovery, and rational development of drug candidates with qualified cellular mechanisms of action. Forma is building a robust pipeline focused on tumor metabolism, epigenetics, and protein-protein interactions. The company is based in Watertown, MA. According to a recent SEC filing, Forma has raised $10 million in venture capital from two investors. FORMA Therapeutics develops a new generation of cancer therapies aimed at previously elusive drug targets. The company applies proprietary cell-based screening, structure-guided drug discovery and Diversity Oriented Synthesis (DOS) technologies. FORMA also uses these technologies to discover novel compounds for partners in indications beyond oncology. The company is headquartered in Cambridge, MA and maintains research operations in Connecticut, Singapore and Beijing. FORMA completed a $25.5M Series B financing to support its programs. With the new funding, the company will advance its internal target-based oncology programs and pursue non-dilutive collaborations to further build its integrated drug discovery platform.

Total raised

$136M

Funding rounds

3

Latest round

Series D

Latest activity

Dec 2019